{"editorial":{"content_id":"e4e2cfbf-083a-4952-a431-f946c14b6602","slug":"ozempic","content_type":"news","title":"巴西首款本土Ozempic仿制药获批，中资药企仿制药出口或面临竞争","summary":"巴西卫生监管机构批准EMS生产的首款本土Ozempic仿制药Ozivy，司美格鲁肽专利3月到期后市场开放，中资原料药及仿制药出口商需关注巴西本土产能替代节奏与注册门槛变化。","body":"巴西卫生监管机构（ANVISA）近日批准了Ozivy，这是该国首款本土生产的Ozempic（司美格鲁肽）仿制药，由巴西最大制药公司之一EMS生产。该批准发生在3月份司美格鲁肽活性成分专利到期之后，标志着巴西在糖尿病和肥胖症治疗药物领域迈出本土化生产的关键一步。对于在巴西从事原料药出口、仿制药注册或医疗健康投资的中资企业而言，这一动态意味着本土替代加速，进口依赖度下降，可能影响现有供应链布局与定价策略。\n\n据巴西媒体The Rio Times报道，巴西卫生监管机构已批准Ozivy，这是该国首款由本土企业生产的Ozempic仿制药。Ozempic主要用于治疗2型糖尿病和肥胖症，其活性成分为司美格鲁肽（semaglutide）。该药由EMS——巴西最大制药公司之一——生产，获批时间紧随3月份司美格鲁肽专利到期之后。Ozivy的适应症与原研药一致，旨在为巴西患者提供更低成本的替代方案。\n\n底稿未涉及中资企业直接影响，但通过以下机制间接传导：首先，巴西本土仿制药上市将直接挤压原研药及进口仿制药的市场份额，对向巴西出口司美格鲁肽原料药或制剂的中资药企构成竞争压力；其次，ANVISA对首款本土仿制药的审批路径可能成为后续仿制药注册的参考标准，中资企业若计划在巴西注册同类产品，需关注ANVISA对生物等效性、本地化生产比例等要求的变化；第三，EMS作为巴西本土巨头，其产能释放节奏将影响中资原料药供应商的订单稳定性。\n\nCBI解读：底稿显示巴西正加速推进关键药物的本土化生产，以降低对进口的依赖并控制公共医疗支出。CBI认为，司美格鲁肽专利到期后，巴西市场将进入仿制药密集获批期，类似2019年印度仿制药企业进入巴西市场的竞争格局。但EMS作为本土龙头，在渠道、医保准入和医生处方习惯上具有先天优势，中资企业若以原料药出口切入，需评估EMS是否自建原料药产能；若以制剂出口或本地化生产切入，则需加快ANVISA注册进度，并考虑与巴西本土药企合作以降低注册壁垒。\n\n待观察：一是EMS的Ozivy正式上市时间及定价策略，预计将在未来3-6个月内公布，这将直接影响其他仿制药的定价空间；二是ANVISA是否会在2026年下半年发布针对司美格鲁肽仿制药的简化注册指南，以加速后续申请；三是其他巴西本土药企（如Hypera、Eurofarma）是否跟进仿制，以及中资原料药供应商（如翰宇药业、诺泰生物）对巴西市场的出口数据变化。","why_it_matters":"巴西首款本土Ozempic仿制药获批，司美格鲁肽专利到期，中资药企仿制药出海面临窗口期与本土竞争双重挑战。","cbi_observation":"底稿显示巴西首款本土Ozempic仿制药获批，这是巴西医药市场里程碑。CBI认为，中资药企需关注ANVISA对本土生产的优先支持，以及后续定价与医保准入政策，否则可能错失窗口期。","direction_tag":"巴西","primary_category":"宏观市场","secondary_topics":["政策","行业趋势","企业动态"],"content_level":"编辑整理","event_type":"企业动态","audience_tags":["在巴中资药企","医药贸易商","原料药供应商"],"event_location":"中资药企、巴西本土药企、原料药供应商","verification_status":"unverified","published_at":"2026-05-26T23:02:26.676Z","display_date":"2026-05-26","source_published_at":null,"source_url":"https://www.riotimesonline.com/brazil-approves-ozivy-ozempic-rival-ems-may-2026/","source_name":"The Rio Times","source_language":"en","author_name":"Clara Lin","risk_level":"low","risk_flags":["regulatory_uncertainty","legal_risk"],"opportunity_flags":["market_entry_opportunity","partnership_opportunity"],"trend_signals":[]},"intelligence":{"intel_id":"5a6e266d-b6c5-4e39-ab33-d1a06d3193bc","version":1,"event_type":"产品上线","event_date":null,"main_entities":[{"name":"EMS","role":"巴西本土仿制药生产商","type":"company","country":"巴西","normalized_name":null},{"name":"ANVISA","role":"巴西卫生监管机构，批准仿制药","type":"regulator","country":"巴西","normalized_name":null},{"name":"Ozivy","role":"巴西首款本土Ozempic仿制药","type":"product","country":"巴西","normalized_name":null},{"name":"诺和诺德","role":"原研药企业","type":"company","country":"其他","normalized_name":null},{"name":"中资药企","role":"潜在仿制药出海参与者","type":"company","country":"中国","normalized_name":null}],"main_action":"巴西ANVISA批准本土药企EMS生产的首款司美格鲁肽仿制药Ozivy，开启仿制药市场。","key_numbers":[],"facts":[{"verified":false,"statement":"巴西卫生监管机构ANVISA批准了Ozivy，这是该国首款本土生产的Ozempic（司美格鲁肽）仿制药。","source_excerpt":null},{"verified":false,"statement":"Ozivy由巴西最大制药公司之一EMS生产。","source_excerpt":null},{"verified":false,"statement":"该药用于治疗2型糖尿病。","source_excerpt":null},{"verified":false,"statement":"此次批准是在2026年3月司美格鲁肽活性成分专利到期后做出的。","source_excerpt":null}],"assessments":[{"statement":"中资药企若仅做出口贸易，可能面临巴西本土企业的价格竞争和监管偏好劣势。","confidence":"medium","basis_fact_index":null},{"statement":"中资药企需加速注册与本地化合作，否则可能错失窗口期。","confidence":"high","basis_fact_index":null},{"statement":"司美格鲁肽仿制药的定价策略和医保准入将直接影响市场容量。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"user","priority":"high","description":"关注Ozivy上市时间、定价及ANVISA后续仿制药申请受理节奏。"},{"target":"user","priority":"high","description":"评估与巴西本土药企合作或建厂的可行性，加快注册审批。"},{"target":"system","priority":"normal","description":"监测诺和诺德可能发起的专利挑战或诉讼。"}],"affected_audience":["在巴西布局仿制药业务的中资企业","巴西2型糖尿病患者","原料药供应商"],"risk_flags":["regulatory_uncertainty","legal_risk"],"opportunity_flags":["market_entry_opportunity","partnership_opportunity"],"trend_signals":[],"follow_up_needed":true,"follow_up_questions":["Ozivy的具体上市时间及定价如何？","ANVISA是否会在2026年下半年加速受理其他企业的仿制药申请？","诺和诺德是否会对EMS或其他仿制药企发起专利挑战或诉讼？"],"related_topics":["巴西医药市场","仿制药","司美格鲁肽","ANVISA","专利到期","中资药企出海"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-05-26T23:02:49.783Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/ozempic","api_url":"https://chinabrazilinsight.com/api/public/content/ozempic","markdown_url":"https://chinabrazilinsight.com/api/public/content/ozempic?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/ozempic?view=json","last_updated":"2026-05-26T23:02:49.803Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}